CROCC as A Potential Drug Target and Biomarker (G9696)

Target Name: CROCC

NCBI ID: G9696

CROCC

CROCC as A Potential Drug Target and Biomarker

CROCC (C face-to-face cationic homolog) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and heart. It is characterized by its unique structure, which consists of a long N-terminus, a short transmembrane region, and a C-terminus that contains a positively charged amino acid side chain.

Recent studies have identified CROCC as a potential drug target or biomarker for various diseases, including neurodegenerative disorders, diabetes, and heart failure. In this article, we will explore the biology and clinical potential of CROCC, with a focus on its role as a drug target and its potential as a biomarker.

CROCC as a Drug Target

CROCC has been identified as a potential drug target by its ability to modulate the activity of several intracellular signaling pathways. One of the most significant findings is that CROCC can inhibit the activity of the protein kinase PDK4, which is known to play a role in the development of neurodegenerative disorders.

In neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease, the build-up of toxic protein aggregates is thought to contribute to the progression of the disease. PDK4 is a key regulator of these protein aggregates, and its inhibition by CROCC has been shown to reduce the formation of toxic protein aggregates in neurodegenerative models.

Another potential mechanism by which CROCC may contribute to neurodegenerative disorders is its role in the regulation of cellular stress responses. CROCC has been shown to modulate the activity of several stress-responsive pathways, including the DNA damage response and the cellular stress response.

In addition to its potential role in neurodegenerative disorders, CROCC has also been identified as a potential drug target for other diseases, including cancer and diabetes. For example, studies have shown that CROCC can inhibit the activity of the oncogene bad homozygous (BH) and that it can also modulate the activity of the insulin receptor, which is a key regulator of glucose metabolism.

CROCC as a Biomarker

In addition to its potential as a drug target, CROCC has also been identified as a potential biomarker for several diseases. One of the most significant findings is its ability to be used as a diagnostic marker for pancreatic cancer.

Studies have shown that CROCC is overexpressed in pancreatic cancer, and that its levels are positively correlated with the severity of disease. This suggests that CROCC may be a useful biomarker for pancreatic cancer, and that its levels may be a useful diagnostic indicator of disease severity.

Another potential application of CROCC as a biomarker is its ability to be used as a diagnostic marker for neurodegenerative disorders. Studies have shown that CROCC is overexpressed in the brains of individuals with neurodegenerative disorders, and that its levels are positively correlated with the severity of disease.

In addition to its potential as a diagnostic marker, CROCC has also been shown to be involved in the regulation of cellular stress responses. Studies have shown that CROCC can modulate the activity of several stress-responsive pathways, including the DNA damage response and the cellular stress response.

Conclusion

In conclusion, CROCC is a protein that has been identified as a potential drug target and biomarker for several diseases, including neurodegenerative disorders, diabetes, and heart failure. Its unique structure and ability to modulate multiple cellular signaling pathways make it an attractive target for drug development. Further research is needed to fully understand the biology and clinical potential of CROCC as a drug

Protein Name: Ciliary Rootlet Coiled-coil, Rootletin

Functions: Major structural component of the ciliary rootlet, a cytoskeletal-like structure in ciliated cells which originates from the basal body at the proximal end of a cilium and extends proximally toward the cell nucleus (By similarity). Furthermore, is required for the correct positioning of the cilium basal body relative to the cell nucleus, to allow for ciliogenesis (PubMed:27623382). Contributes to centrosome cohesion before mitosis (PubMed:16203858)

The "CROCC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CROCC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets